Eli Lilly and Company’s (LLY) “Outperform” Rating Reiterated at Wolfe Research

Eli Lilly and Company (NYSE:LLY)‘s stock had its “outperform” rating restated by analysts at Wolfe Research in a research note issued to investors on Monday,Benzinga reports. They currently have a $1,325.00 price target on the stock. Wolfe Research’s price target would suggest a potential upside of 37.29% from the company’s previous close.

LLY has been the topic of a number of other research reports. Leerink Partners cut their price objective on shares of Eli Lilly and Company from $1,296.00 to $1,058.00 and set an “outperform” rating on the stock in a research report on Monday, April 27th. HSBC lowered Eli Lilly and Company from a “hold” rating to a “reduce” rating and decreased their target price for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Scotiabank reiterated an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. Bank of America reduced their price objective on Eli Lilly and Company from $1,294.00 to $1,133.00 and set a “buy” rating for the company in a research note on Friday. Finally, Truist Financial restated a “buy” rating on shares of Eli Lilly and Company in a report on Monday, February 23rd. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,217.59.

Eli Lilly and Company Trading Up 0.2%

Shares of NYSE:LLY traded up $1.79 during mid-day trading on Monday, hitting $965.12. The company had a trading volume of 1,702,491 shares, compared to its average volume of 3,176,690. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The firm has a fifty day moving average price of $947.05 and a 200 day moving average price of $987.36. The company has a market capitalization of $911.86 billion, a PE ratio of 34.24, a price-to-earnings-growth ratio of 1.13 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. The business had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. Eli Lilly and Company’s revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the firm earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts forecast that Eli Lilly and Company will post 33.79 EPS for the current year.

Institutional Trading of Eli Lilly and Company

Institutional investors and hedge funds have recently modified their holdings of the stock. Uptick Partners LLC raised its holdings in shares of Eli Lilly and Company by 8.8% in the first quarter. Uptick Partners LLC now owns 738 shares of the company’s stock valued at $679,000 after purchasing an additional 60 shares during the last quarter. AMF Tjanstepension AB boosted its holdings in Eli Lilly and Company by 2.8% during the first quarter. AMF Tjanstepension AB now owns 477,177 shares of the company’s stock worth $438,893,000 after purchasing an additional 13,138 shares during the last quarter. Triglav Investments D.O.O. grew its position in Eli Lilly and Company by 3.3% in the 1st quarter. Triglav Investments D.O.O. now owns 49,212 shares of the company’s stock worth $45,265,000 after purchasing an additional 1,566 shares in the last quarter. Y.D. More Investments Ltd increased its stake in Eli Lilly and Company by 9.8% in the 1st quarter. Y.D. More Investments Ltd now owns 900 shares of the company’s stock valued at $797,000 after buying an additional 80 shares during the last quarter. Finally, J. Safra Sarasin Holding AG increased its stake in Eli Lilly and Company by 8.8% in the 1st quarter. J. Safra Sarasin Holding AG now owns 89,613 shares of the company’s stock valued at $82,380,000 after buying an additional 7,285 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Q1 results and raised guidance: Lilly reported $19.8B revenue and $8.55 EPS (well above estimates) and gave FY?2026 EPS guidance, underpinning optimism about its obesity franchise and margin expansion. LLY Q1 Deep Dive
• Positive Sentiment: Big analyst support: Barclays raised its price target to $1,400 and kept an overweight rating, signaling continued upside expectations. Elevated price targets/Buy reiterations from other firms (Truist, BofA) are sustaining bullish sentiment. Barclays adjusts Eli Lilly price target
• Positive Sentiment: Dividend declared: Board announced a $1.73/share Q2 dividend, payable June 10 — supports income appeal for long?term holders. Lilly declares second-quarter 2026 dividend
• Neutral Sentiment: Investor interest and commentator coverage remains high: outlets (Zacks, The Motley Fool, 247WallStreet) highlight the company’s growth story and keep the name in retail/quant screens — supports liquidity but not a catalyst by itself. Eli Lilly is attracting investor attention
• Negative Sentiment: FDA safety flags: The FDA has logged serious liver?related cases in patients taking Foundayo — this is the primary near?term negative catalyst and is prompting investor concern about labeling, usage limits, or additional data requests. FDA Reports Liver Failure in Patient Taking Lilly’s Foundayo
• Negative Sentiment: Market reaction and coverage: Multiple outlets reported a stock pullback after the liver?safety reports; some analysts call the move an overreaction, but near?term volatility is likely as investors await regulatory/clinical follow?up. Eli Lilly Dips After Weight-Loss Patient Reports A Surprise Side Effect

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.